bet inhibitor resistance emerges leukaemia stem cells 
bromodomain extra terminal protein bet inhibitors first-in-class targeted therapies deliver newtherapeutic opportunity directly targeting bromodomain proteins bind acetylated chromatin marks12 early clinical trials shown promise especially acute myeloid leukaemia3 therefore evaluation resistance mechanismsis crucial optimize clinical efficacy drugs use primary mouse haematopoietic stem progenitor cells immortalized fusion protein mll-af9 generate several single-cell clones demonstrate resistance vitro vivo prototypical bet inhibitor i-bet resistance i-bet confers cross-resistance chemically distinct bet inhibitors jq1 well resistance genetic knockdown bet proteins resistance notmediated increased drug efflux metabolism shown emerge leukaemia stem cells ex vivo vivo chromatin-bound brd4 globally reduced resistant cells whereas expression key target genes myc remains unaltered highlighting existence alternative mechanisms regulate transcription demonstrate resistance bet inhibitors human mouse leukaemia cells part consequence increasedwnt/beta-catenin signalling negative regulation pathway results restoration sensitivity i-bet vitro vivo together findings provide new insights biology acute myeloid leukaemia highlight potential therapeutic limitations bet inhibitors identify strategies may enhance clinical utility unique targeted therapies 
